Methods of treating hypertriglyceridemia

• US 10,632,094 B2
• Filed: 06/10/2019
• Issued: 04/28/2020
• Est. Priority Date: 11/07/2011
• Status: Active Grant

• Current Assignee: Amarin Pharmaceuticals Ireland Limited (Amarin Corporation plc)
• Original Assignee: Amarin Pharmaceuticals Ireland Limited (Amarin Corporation plc)
• Inventors: Manku, Mehar, Osterloh, Ian, Wicker, Pierre, Braeckman, Rene, Soni, Paresh
• Primary Examiner(s): Rao, Savitha M
• Application Number:
  US16/436,364
• Publication Number:
  US 20200061012A1
• Time in Patent Office: 323 Days
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/232 having three or more double bonds, e.g. etretinate
• CPC Class Codes: A61P 3/06 Antihyperlipidemics

Abstract

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Claims

1. A method of reducing small LDL particle concentration in a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl and a baseline small LDL particle concentration of about 800 nmol/L to about 1400 nmol/L, comprising, administering to the subject about 4 g per day of ethyl eicosapentaenoate thereby to produce a reduction in small LDL particle concentration by comparison with a baseline small LDL particle concentration prior to initiation of administration, wherein the small LDL particle has a diameter of 18.0-20.5 nm.

2. The method of claim 1 wherein the reduction in small LDL particle concentration is at least a 5% reduction.

3. The method of claim 1 wherein the reduction in small LDL particle concentration is at least a 9% reduction.

4. The method of claim 1 wherein the subject is administered about 3.8 g to about 4 g per day of ethyl eicosapentaenoate.

5. The method of claim 1 wherein the subject is administered ethyl eicosapentaenoate for a period of 12 weeks.